Literature DB >> 22589393

Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy.

Andrea Salonia1, Firas Abdollah, Umberto Capitanio, Nazareno Suardi, Alberto Briganti, Andrea Gallina, Renzo Colombo, Matteo Ferrari, Giulia Castagna, Patrizio Rigatti, Francesco Montorsi.   

Abstract

PURPOSE: To assess the association between preoperative serum total testosterone (tT), 17β-estradiol (E(2)), sex hormone-binding globulin (SHBG), and tT-E(2) ratio values with high-risk prostate cancer (as defined by the National Comprehensive Cancer Network practice guidelines) at radical prostatectomy. EXPERIMENTAL
DESIGN: Serum E(2), tT, and SHBG were dosed the day before surgery (7:00-11:00 am) in a cohort of 724 candidates to radical prostatectomy. Restricted cubic spline functions tested the association between predictors (i.e., model 1: age, body mass index, and serum tT, E(2), and SHBG levels; model 2: tT-E(2) values instead of tT and E(2) levels) and high-risk prostate cancer.
RESULTS: Low-, intermediate-, or high-risk prostate cancer was found in 251 (34.7%), 318 (43.9%), and 155 (21.4%) patients, respectively. Patients in the high-risk class showed the lowest tT, E(2), and tT-E(2) ratio values (all P ≤ 0.02). At univariate analysis, only age, tT, E(2), and tT-E(2) ratio values were significantly associated with high-risk prostate cancer (all P ≤ 0.006). At multivariate analyses considering model 1 variables, age (P = 0.03), serum tT (all P < 0.001), and E(2) (all P ≤ 0.01) were associated with high-risk prostate cancer; only tT-E(2) ratios achieved independent predictor status for high-risk prostate cancer (all P < 0.001) when considering model 2. Both the lowest and the highest tT, E(2), and tT-E(2) values depicted a nonlinear U-shaped significant association with high-risk prostate cancer.
CONCLUSIONS: These data showed that preoperative serum sex steroids are independent predictors of high-risk prostate cancer, depicting a nonlinear U-shaped association. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22589393     DOI: 10.1158/1078-0432.CCR-11-2799

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

Review 1.  Testosterone therapy and prostate cancer--safety concerns are well founded.

Authors:  Laurence Klotz
Journal:  Nat Rev Urol       Date:  2015-01       Impact factor: 14.432

Review 2.  Testosterone Therapy Among Prostate Cancer Survivors.

Authors:  Taylor M Nguyen; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2016-07-27

3.  Preoperative Plasma Levels of Total Testosterone Associated with High Grade Pathology-Detected Prostate Cancer: Preliminary Results of a Prospective Study in a Contemporary Cohort of Patients.

Authors:  Antonio B Porcaro; Nicolò De Luyk; Paolo Corsi; Marco Sebben; Alessandro Tafuri; Giovanni Cacciamani; Davide De Marchi; Irene Tamanini; Davide Inverardi; Matteo Brunelli; Maria A Cerruto; Gian L Salvagno; Gian C Guidi; Walter Artibani
Journal:  Curr Urol       Date:  2017-05-30

Review 4.  Testosterone Therapy in Men With Prostate Cancer.

Authors:  Alan L Kaplan; Jim C Hu; Abraham Morgentaler; John P Mulhall; Claude C Schulman; Francesco Montorsi
Journal:  Eur Urol       Date:  2015-12-21       Impact factor: 20.096

5.  Hypogonadism and prostate cancer detection on multiparametric MRI and mpMRI-TRUS fusion biopsy.

Authors:  Dordaneh Sugano; Abhinav Sidana; Amit L Jain; Brian Calio; Sonia Gaur; Mahir Maruf; Maria Merino; Peter Choyke; Baris Turkbey; Bradford J Wood; Peter A Pinto
Journal:  Int Urol Nephrol       Date:  2019-12-05       Impact factor: 2.370

Review 6.  Hypogonadism and its treatment among prostate cancer survivors.

Authors:  Edward J Choi; Perry Xu; Farouk M El-Khatib; Linda M Huynh; Faysal A Yafi
Journal:  Int J Impot Res       Date:  2020-12-12       Impact factor: 2.896

7.  LHRH and LHR genotypes and prostate cancer incidence and survival.

Authors:  Sue Ann Ingles; Stephen V Liu; Jacek Pinski
Journal:  Int J Mol Epidemiol Genet       Date:  2013-11-28

8.  Circulating sex steroids and prostate cancer: introducing the time-dependency theory.

Authors:  Andrea Salonia; Firas Abdollah; Umberto Capitanio; Nazareno Suardi; Andrea Gallina; Giulia Castagna; Maria Chiara Clementi; Alberto Briganti; Patrizio Rigatti; Francesco Montorsi
Journal:  World J Urol       Date:  2013-01-03       Impact factor: 4.226

Review 9.  The Role of Testosterone Therapy in the Setting of Prostate Cancer.

Authors:  Katherine M Rodriguez; Alexander W Pastuszak; Mohit Khera
Journal:  Curr Urol Rep       Date:  2018-06-30       Impact factor: 3.092

Review 10.  Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer.

Authors:  A Fucic; A Aghajanyan; Z Culig; N Le Novere
Journal:  Pathol Oncol Res       Date:  2018-09-16       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.